J&J to stop studies of depression drug due to low effectiveness
(Reuters) -Johnson & Johnson will stop late-stage studies of its experimental drug to treat major depressive disorder due to ...
Psychedelic: MindMed reports Q4 earnings results
In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on earnings, a study approval ...
Hosted on MSN12h
Elon Musk’s Ketamine Chronicles: Should We Be Concerned?
Musk is regularly using ketamine—a dissociative anesthetic known for its hallucinogenic effects, cognitive impairment risks, ...
Managed Healthcare Executive6h
FDA Approves Neffy 1 mg Nasal Spray for Pediatric Patients
Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 ...
Healio5h
FDA approves epinephrine nasal spray for children aged as young as 4 years
The FDA has approved neffy 1 mg epinephrine nasal spray for treating anaphylaxis and other type 1 allergic reactions in ...
WebMD9h
FDA OKs Nasal Spray for Severe Allergic Reactions in Kids
The FDA has approved Neffy, a needle-free nasal spray, for children aged 4 and up, providing fast and effective treatment for severe allergic reactions and anaphylaxis.
BioSpace12h
ARS Wins FDA Approval for Neffy Spray for Children in Anaphylaxis
Neffy 1 mg is the “first significant innovation” for epinephrine delivery in small children aged 4 years and up in over 35 ...
San Diego biotech gets FDA approval for epi-pen alternative for kids
Parents and pediatricians just gained one more tool to combat severe allergic reactions in young kids. San Diego-based ARS ...